Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258369 | 0.88 | GAA (0.55) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL606590 | 0.84 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL2168517 | 0.84 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL2168521 | 0.84 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1427228 | 0.84 | MGAM (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL3853840 | 0.84 | MGAM (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL9743315 | 0.84 | MGAM (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1895727 | 0.82 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL3064787 | 0.82 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL3064783 | 0.82 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007506661-A | — | — | 2007-03-22 | — | — | JP | claimed |
| US-20070037846-A1 | Pyrazolidinedione derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-15 | — | — | US | claimed |
| EP-1638540-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-29 | — | — | EP | claimed |
| WO-2005000281-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20070037846-A1 | Pyrazolidinedione derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-15 | — | — | US | disclosed |
| EP-1638540-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000281-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037846-A1 | Pyrazolidinedione derivatives | P2RY1, P2RY4, P2RY2 | MGAM 4610/4885GAA 3492/4885SI 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.